Tenaya Shares Rise on Positive Data From ARVC Study

Dow Jones

05/15

By Nicholas G. Miller

Tenaya Therapeutics shares rose after the company reported positive interim data from a trial of its gene therapy to treat arrhythmogenic right ventricular cardiomyopathy.

The stock rose 4.8% to 98 cents in premarket trading. It has more than doubled over the past 12 months.

The biotechnology company said the Phase 1b/2 trial demonstrated consistent and deep reductions in premature ventricular contractions.

Tenaya's chief medical officer, Whit Tingley, said the trial has shown consistent improvements in ventricular electrical stability, which is predicted to "decrease the risk for more serious, life-threatening arrhythmias."

The therapy was also well-tolerated at both dose levels in the study, the company said

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

May 15, 2026 07:14 ET (11:14 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2635862200"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635862200\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635862200?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 19:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635862200","market":"sg","top_or_hot":-1,"title":"Tenaya Shares Rise on Positive Data From ARVC Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Tenaya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares rose after the company reported positive interim data from a trial of its gene therapy to treat arrhythmogenic right ventricular cardiomyopathy. \n</p>\n<p>\n  The stock rose 4.8% to 98 cents in premarket trading. It has more than doubled over the past 12 months. \n</p>\n<p>\n  The biotechnology company said the Phase 1b/2 trial demonstrated consistent and deep reductions in premature ventricular contractions. \n</p>\n<p>\n  Tenaya's chief medical officer, Whit Tingley, said the trial has shown consistent improvements in ventricular electrical stability, which is predicted to \"decrease the risk for more serious, life-threatening arrhythmias.\" \n</p>\n<p>\n  The therapy was also well-tolerated at both dose levels in the study, the company said \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2026 07:14 ET (11:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tenaya Shares Rise on Positive Data From ARVC Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenaya Shares Rise on Positive Data From ARVC Study\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-05-15 19:14</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Tenaya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares rose after the company reported positive interim data from a trial of its gene therapy to treat arrhythmogenic right ventricular cardiomyopathy. \n</p>\n<p>\n  The stock rose 4.8% to 98 cents in premarket trading. It has more than doubled over the past 12 months. \n</p>\n<p>\n  The biotechnology company said the Phase 1b/2 trial demonstrated consistent and deep reductions in premature ventricular contractions. \n</p>\n<p>\n  Tenaya's chief medical officer, Whit Tingley, said the trial has shown consistent improvements in ventricular electrical stability, which is predicted to \"decrease the risk for more serious, life-threatening arrhythmias.\" \n</p>\n<p>\n  The therapy was also well-tolerated at both dose levels in the study, the company said \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2026 07:14 ET (11:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"半新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635862200","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635862200","pubTimestamp":1778843640,"columns":[{"name":"行業數據","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Tenaya Therapeutics shares rose after the company reported positive interim data from a trial of its gene therapy to treat arrhythmogenic right ventricular cardiomyopathy.The stock rose 4.8% to 98 cents in premarket trading. It has more than doubled over the past 12 months.The biotechnology company said the Phase 1b/2 trial demonstrated consistent and deep reductions in premature ventricular contractions.Tenaya's chief medical officer, Whit Tingley, said the trial has shown consistent improvements in ventricular electrical stability, which is predicted to \"decrease the risk for more serious, life-threatening arrhythmias.\". The therapy was also well-tolerated at both dose levels in the study, the company said","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","TNYA":"Tenaya Therapeutics Inc"},"translate_title":"ARVC研究的积极数据使Tenaya股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNYA":0.9},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Tenaya Therapeutics shares rose after the company reported positive interim data from a trial of its gene therapy to treat arrhythmogenic right ventricular cardiomyopathy. \n\n\n  The stock rose 4.8% to 98 cents in premarket trading. It has more than doubled over the past 12 months. \n\n\n  The biotechnology company said the Phase 1b/2 trial demonstrated consistent and deep reductions in premature ventricular contractions. \n\n\n  Tenaya's chief medical officer, Whit Tingley, said the trial has shown consistent improvements in ventricular electrical stability, which is predicted to \"decrease the risk for more serious, life-threatening arrhythmias.\" \n\n\n  The therapy was also well-tolerated at both dose levels in the study, the company said \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 07:14 ET (11:14 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}